Clinic Dispensing, Doctor Dispensing, Employer Clinic, Employer Health Benefits, In Office Dispensing, news, Northwind Pharmaceuticals

Pharmacy Innovation Leads to Cheaper Rx – Healthcare Americana Podcast

Listen to Freedom Healthworks CEO Christopher Habig and Northwind Pharmaceuticals CEO Phillip Berry discuss healthcare and pharma trends in this podcast. Prescription drugs are a focal point for any discussion on the cost of healthcare and the requisite innovations of modern medicine. The treatment of acute and chronic conditions are aided by prescription medicine, but recently, price increases have been escalating and people are concerned about affording their needed medications. Pharmaceutical innovators like Northwind are changing the game by refusing to play in the “established” system of pharmaceutical distribution.

Click the link below to go to the podcast:

Pharmacy Innovation Leads to Cheaper Rx

Schedule a free claims analysis now.

Let’s Talk now

Leader in AI-driven health benefits navigation Healthee partners with Northwind

Katherine Lurk | Mar 28th, 2025
A game-changer for employers looking to cut costs and gain control With healthcare costs continuing to rise, employers are seeking new ways to rein in spending without sacrificing the quality of benefits. This partnership enables Healthee clients to optimize prescription drug management, reducing costs through preferable generic drug pricing, high-touch chronic care programs, and more. … more »

continue reading

Healthcare Storm 2025: What Will It Be?

Phillip Berry | Jan 1st, 2025
When it comes to American healthcare, we’ve become really good at highlighting its failings. Watching the flurry of lamentations, frustrations, denigrations, and prognostications, over the last few weeks, would lead any rational person to believe that nothing is working in our healthcare system. And, not only is it “not working,” many people conclude that it … more »

continue reading

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading